Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSharp Health Plan Formulary Coverage & Prior Auth …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentSharp-Health-PlanPolicy N/A

    Sharp Health Plan Prescription Drug List (Formulary) — Employer‑Sponsored Plans

    Customize your policy alerts

    Sign up for all Sharp-Health-Plan policy alerts

    Know when Sharp-Health-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Sharp Health Plan prescription drug list (formulary) for employer‑sponsored plans and specific HMO/POS/HDHP products, describing covered outpatient prescription drugs, plan applicability, and formulary policies. It affects providers, pharmacists, and members enrolled in the listed Sharp Health Plan products.

    Policy Summary
    PayerSharp-Health-Plan
    PolicyPrescription Drug List (Formulary) — Employer‑Sponsored Plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit Prior Authorization with supporting clinical documentation when a drug is marked PA or SP on the formulary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Mar 2026last updated
    Availableonline formulary
    60 daysmember notice period
    Many productsPA common
    QuarterlyP&T frequency

    Coverage Criteria & Formulary Rules

    General Coverage Criteria

    Covered when ALL of the following general benefit and medical necessity conditions are met:

    Outpatient prescription drug benefit: Drug is FDA‑approved for outpatient use and included on the Formulary; outpatient pharmacy benefit covers drugs dispensed through network retail, specialty, or mail order pharmacies (oral or topical unless otherwise listed).

    From Formulary Introduction

    Medical vs Medical Benefit: Drugs that are physician‑administered or self‑injectable may be covered under the Medical Benefit rather than the outpatient pharmacy benefit; refer to the Member Handbook for benefit determination and cost‑share information.

    See Introduction: Medical Benefit exceptions

    Prior authorization / Exception: If the Formulary or coverage requirements indicate 'PA' or the drug is non‑formulary, a Prior Authorization or Formulary Exception must be requested and approved for coverage; Sharp Health Plan will grant prior authorization when medically necessary.
    Policy Summary
    PayerSharp-Health-Plan
    PolicyPrescription Drug List (Formulary) — Employer‑Sponsored Plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit Prior Authorization with supporting clinical documentation when a drug is marked PA or SP on the formulary.
    SourceLink
    On This Page
    Coverage Criteria & Formulary RulesFormulary Listings & CodesWhat Providers Must DoInitial Therapy RequirementsStep Therapy Rules & TablesQuantity Limits & ExamplesSpecialty, Mail Order & Retail RoutingBiologics & Interchangeable ProductsBackground & ScopeKey Terms & Symbols

    See Prior Authorization definition and Formulary Exception rules

    Step Therapy: When a drug row is marked 'ST' the member must meet Step Therapy requirements (trial of preferred alternative(s)) unless a Step Therapy Exception is approved; exceptions are processed via the Prior Authorization process.

    See Step Therapy definition

    General Formulary Coverage

    Coverage is governed by formulary listing, tier assignment, and applicable utilization controls. Coverage for non‑formulary or brand when a generic exists requires authorization and may change cost‑sharing.

    Formulary listing and tiering: Member coverage requires the drug be listed on the Sharp Health Plan Formulary and is subject to the drug's assigned Drug Tier (affects member cost share).

    Formulary listing and Drug Tier (see Formulary definitions)

    Utilization controls must be satisfied: Coverage is conditional on fulfillment of any applicable utilization controls indicated on the Formulary row (PA, PA**, ST, QL, SP, MO, OAC). Prescriber must submit Prior Authorization or Step Therapy Exception where indicated.

    See symbols: PA, PA**, QL, ST, SP, MO, OAC

    Brand vs generic dispensing: Contracted pharmacies are required to dispense the generic when available; dispensing the Brand‑Name or reference biologic instead requires prior authorization and medical necessity documentation.

    Generic substitution / biosimilar substitution policy

    Formulary exceptions and nonformulary drugs: Nonformulary drugs are not covered unless a Formulary Exception is approved via the Prior Authorization process; approved nonformulary brands/generics are subject to specified tier cost shares.

    Formulary Exception procedure

    Excluded Uses

    The Plan does not cover the following outpatient prescription drug uses except as required by law:

    Cosmetic uses: Drugs prescribed for cosmetic services (defined as drugs intended to alter appearance rather than function).

    Exclusion 1

    Non‑therapeutic enhancement: Drugs prescribed solely for hair loss, sexual dysfunction, athletic performance, anti‑aging for cosmetic purposes, or mental performance (unless medically necessary to treat diagnosed mental illness or conditions affecting memory).

    Exclusion 2

    Weight loss: Drugs prescribed solely for weight loss are excluded except when medically necessary for Class III obesity; enrollment in a comprehensive weight‑loss program may be required prior to or concurrent with drug coverage.Class III obesity for coverage

    Exclusion 3

    Common cold duration: Drugs prescribed solely to shorten the duration of the common cold are excluded.

    Exclusion 4

    OTC equivalents: Prescription drugs available over‑the‑counter or with an OTC equivalent (same active ingredient/strength/dosage form) are excluded, except for insulin, certain preventive OTCs (e.g., contraceptives), OTC opioid reversal agents, or when an entire class becomes OTC.

    Exclusion 5

    Replacement of lost/stolen drugs: Replacement of lost or stolen drugs is not covered.

    Exclusion 6

    Non‑contracting providers: Drugs prescribed by non‑contracting providers for non‑covered procedures not authorized by the plan are not covered, except as required in emergency contexts.

    Exclusion 7

    Opioid ER — Step Therapy

    Coverage for certain extended‑release (ER) opioid products is provided only when specific prior use (step therapy) criteria are met:

    Opioid ER Step Therapy criteria: Coverage will be provided if the member has filled a cumulative ≥7‑day supply of an immediate‑release opioid within the past 90 days OR has been receiving an extended‑release opioid for a cumulative ≥30 days within the past 90 days.>=7 days IR within 90 days OR >=30 days ER within 90 days

    Applies to Step Therapy Group OPIOID ER 2219‑M (e.g., BELBUCA, fentanyl, hydrocodone ER, morphine ER, etc.)

    Opioid IR combo — Short supply allowance

    Short‑supply allowance for immediate‑release (IR) opioid combination products when prior opioid use is absent:

    IR opioid short supply allowance: If the member does not have at least a cumulative 7‑day supply of any opioid (IR or ER) within the past 90 days, coverage will be provided for up to a 7‑day supply of immediate‑release opioid combination products.<=7‑day supply when no >=7‑day prior opioid supply in past 90 days

    Applies to Step Therapy Group OPIOID IR COMBO PRODUCTS 1358‑E

    Amphetamines — PA and QL

    Amphetamine‑class products are covered when ALL of the following are satisfied:

    Prior authorization: Most amphetamine formulations and strengths require Prior Authorization (PA) as indicated on the Formulary row.PA

    PA commonly required for age ≥19

    Quantity limits: Dispensing must not exceed the product‑specific Quantity Limit (QL) shown on the Formulary row (examples: 360 tabs/75 days; 180 caps/75 days; 90 caps/75 days; 270 caps/75 days).QL per product

    See product rows for exact QL

    Age‑based PA requirement: For many amphetamine and stimulant products, PA is required for members age ≥19; prescriber must document age when requesting PA.age >= 19

    Age documentation required for PA requests

    Coverage when requirements are met

    Coverage stance is product‑specific; drugs listed below are COVERED when ALL listed product controls are met:

    Prior authorization required for many agents: Prior Authorization (PA) is required for the majority of listed amphetamine, anti‑obesity, ADHD, stimulant and related agents as indicated on their Formulary rows.PA

    See individual product entries for PA/PA**

    Quantity limits must be followed: Products with QL must be dispensed within the specified quantity limits; exceptions require PA with documentation of medical necessity.QL per product

    Examples: atomoxetine 360 caps/75 days; WAKIX 2 tabs/day; methylphenidate QLs vary (540 tabs/75 days etc.)

    Age‑based PA rules: For many ADHD/stimulant formulations and select products (e.g., atomoxetine, methylphenidate, AZSTARYS), PA is required for members age ≥19.age >= 19

    PA documentation required for adult prescriptions

    Product-level coverage with PA/QL/MO controls

    Covered when the following product‑level controls (as shown in each Formulary row) are satisfied:

    Product‑level PA and QL example (methylphenidate chewable): Product is on the Formulary but coverage requires Prior Authorization and adherence to the stated Quantity Limit (e.g., methylphenidate chewable: PA; QL = 540 tabs every 75 days) and PA is required for members age ≥19.age >=19; QL=540/75 days

    Example row: methylphenidate chew tab 10 mg

    Opioid high-strength coverage

    Coverage for opioid and certain analgesic products is conditional; coverage is provided when product‑level prior authorization, step therapy, and quantity limits are satisfied:

    High‑strength opioid coverage: High‑strength formulations (as identified on the Formulary row) require Prior Authorization; coverage may also require meeting Step Therapy (ST) or PA** conditions.High‑strength requires PA

    Examples: fentanyl patches above certain strengths, high‑strength hydrocodone/morphine/oxycodone

    Step Therapy for some ER/transdermal opioids: Select ER/transdermal opioid products are designated ST and require meeting step therapy criteria prior to approval (see opioid step therapy group).ST as indicated

    Applies to select fentanyl patches, hydrocodone ER, morphine ER, tramadol ER 100 mg

    Initial supply limits

    Initial supply limits apply to many immediate‑release opioid prescriptions and certain oral formulations:

    Initial supply limits for opioids: Most immediate‑release opioid prescriptions are subject to an initial 7‑day supply limit for adults; members age 19 or younger are subject to an initial 3‑day limit where stated on the Formulary rows.Initial 7‑day (adults) / 3‑day (<=19 years)

    Applies to many IR opioid liquids and tablets; prescriber should request PA for quantities beyond initial limit

    Tramadol coverage

    Tramadol coverage is subject to age restrictions and utilization management controls:

    Tramadol coverage requirements: Tramadol products are not available for members under age 12; formulations are subject to PA and QL and certain ER strengths are designated ST or require PA/PA**; initial supply limits apply (7‑day adult / 3‑day if age ≤19).Not available < age 12; initial 7‑day / 3‑day <=19

    Examples: tramadol oral solution QL 1800 mL/25 days; tramadol IR 50 mg QL 180 tabs/25 days; ER 100 mg ST/PA**

    Product-level PA + QL + age restrictions

    Covered with prior authorization and quantity limits when the following product‑level conditions are met:

    Product‑level PA + QL + age restrictions: Coverage is allowed when the product‑specific Prior Authorization (PA or PA**), Quantity Limit (QL), and any age restrictions shown on the Formulary row are satisfied; high‑strength products require PA and some products are subject to Step Therapy.See Formulary row: PA/PA**; QL; age limits

    Applies across opioid, buprenorphine, testosterone and other product groups

    Coverage designations

    Coverage and limits are specified per drug entry; coverage depends on the designation shown on each Formulary row:

    Coverage designations: Formulary rows include DRUG TIER and coverage requirement codes such as PA (Prior Authorization), MO (Medical Only), QL (Quantity Limit), SP (Specialty). Coverage is conditional on satisfying the indicated designation.

    See Formulary symbols/definitions

    Drug listing and modifiers

    Each Formulary line item indicates tier and any coverage requirement/limit flags; coverage is conditional on those flags being met:

    Formulary line item requirements: Each listed drug row includes the drug name, strength/formulation, assigned Drug Tier and a COVERAGE REQUIREMENTS AND LIMITS field (typical values: QL, PA, SP, MO); prescribers/pharmacies must comply with the requirements shown for a specific product and strength.

    Consult pharmacy system or Formulary row for operational PA/QL details

    Formulary coverage with quantity limits

    Covered when dispensed within the formulary product, assigned tier, and stated quantity limits:

    Formulary product + tier + QL: A drug is covered provided it is the listed product/formulation, dispensed consistent with its Drug Tier, and within the stated Quantity Limit; requests exceeding QL or outside tier rules require Prior Authorization and may be denied if not supported by medical necessity.QL per product

    Examples: inhalers and nebulizer QLs; oral/tablet QLs per product rows

    Formulary status and shorthand coverage annotations

    Drugs are listed with drug tier and short coverage annotations; specific clinical criteria to satisfy PA/MO are not provided in this excerpt:

    Formulary tier and shorthand annotations: Individual drug entries include a DRUG TIER assignment and COVERAGE REQUIREMENTS/NOTES codes (examples: MO, PA, SP, QL). For detailed clinical PA criteria, providers must reference the Plan's PA criteria or submit a PA request with supporting documentation.

    This excerpt shows tier/flags but not full PA clinical criteria

    Coverage status (partial)

    Products are listed with coverage requirement abbreviations; coverage is conditional based on those requirements:

    Coverage status (conditional): Formulary entries show coverage requirement codes (e.g., PA, QL, SP, MO); absence of a detailed clinical rule in this segment means providers must follow the PA/QL/SP processes described elsewhere in the Formulary when requesting coverage.

    Coverage conditional on indicated flags

    Formulary listing with management flags

    Coverage is indicated per drug with drug tier and coverage requirement flags; specific clinical PA criteria are referenced but not included in this excerpt:

    Formulary listing with management flags: Each product row includes a DRUG TIER and COVERAGE REQUIREMENTS AND LIMITS tag (examples: MO, PA, QL, SP). Where flags appear, prescribers must submit required documentation to satisfy the indicated requirement before coverage is approved.

    Detailed PA clinical criteria are maintained in Plan PA documentation

    This formulary is a living document and subject to change. The electronic Prescription Drug List posted at the Sharp Health Plan website is the controlling version. All previous versions are no longer in effect and coverage, tiering, or utilization controls may be revised without further update to older copies of this extract. Providers should confirm current coverage status and requirements via the plan portal or pharmacy system before dispensing or submitting authorization requests.

    Drugs and supplies that fall within the outpatient prescription drug benefit exclusions described in the Member Handbook are not eligible for a coverage Exception Request and are not covered under the outpatient pharmacy benefit. In addition, when a generic equivalent is available the plan requires pharmacies to dispense the generic unless prior authorization for the brand is obtained; similar substitution rules apply for interchangeable biological products unless a prior authorization for the reference biologic is granted.

    The Plan excludes prescriptions written solely for non‑therapeutic or cosmetic purposes. Examples of excluded uses include drugs prescribed for cosmetic purposes, hair loss, sexual dysfunction, athletic performance enhancement, and anti‑aging for cosmetic purposes. These exclusions apply except where coverage is required by law or the drug is medically necessary for a diagnosed condition.

    Excluded outpatient prescription uses include, but are not limited to: cosmetic procedures; treatment solely for hair loss, sexual dysfunction, athletic performance, and anti‑aging (cosmetic); agents intended only for enhancement of mental performance (unless medically necessary to treat a diagnosed mental illness or conditions that impair memory); drugs prescribed only to shorten the common cold; over‑the‑counter equivalents (with specified exceptions); replacement of lost or stolen medications; and drugs prescribed by non‑contracting providers for non‑covered procedures.

    Formulary Listings & Codes

    Covered prescription drug listings (therapeutic classes)mixed
    N/AAlphabetical lists of covered drugs by therapeutic class are provided (chunks 18-25). Specific billing codes (CPT/HCPCS/NDC/ICD-10) are not present in this excerpt.
    Listed stimulants/anti-obesity productsmixed
    diethylpropion hcl tab er 24hr 75 mgListed drug with DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phendimetrazine tartrate tab 35 mgGeneric drug DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl cap 15 mgGeneric drug DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl cap 30 mgGeneric drug DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl cap 37.5 mgGeneric drug DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    Phentermine Hcl Tab 8 mg (LOMAIRA)Brand drug DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    Anti-obesity agentsmixed
    phentermine hcl-topiramate cap er 3.75-23 mgGeneric; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl-topiramate cap er 7.5-46 mgGeneric; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl-topiramate cap er 11.25-69 mgGeneric; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    phentermine hcl-topiramate cap er 15-92 mgGeneric; DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    QSYMIA caps (3.75-23; 7.5-46; 11.25-69; 15-92 mg)Brand DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA
    orlistat cap 120 mgGeneric DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA
    WEGOVY tabs (1.5 mg; 4 mg; 9 mg; 25 mg) semaglutide (weight management)ND/Brand DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA; 9mg and 25mg entries include PA and MO notices
    ADHD, narcolepsy, and stimulant agents with QL/PA/MOmixed
    Atomoxetine caps (10,18,25,40,60,80,100 mg)Generic DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA; QL examples: 360/75 days down to 90/75 days; PA required for age >=19
    Clonidine ER 12hr 0.1 mgGeneric DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    Guanfacine ER 24hr (1,2,3,4 mg)Generic DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = MO
    QELBREE caps (viloxazine) 100,150,200 mg ERBrand DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = QL (270 caps/75 days), MO
    SUNOSI tabs 75 mg, 150 mg (solriamfetol)DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA, MO
    WAKIX tabs 4.45 mg, 17.8 mg (pitolisant)Brand DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = SP, PA, QL (2 tabs/day)
    Armodafinil tabs (50,150,200,250 mg)DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA, MO
    AZSTARYS caps (multiple strengths)Brand DRUG TIER = 2; COVERAGE REQUIREMENTS AND LIMITS = PA, QL (90 caps/75 days), MO; age >=19 PA requirement noted
    Dexmethylphenidate ER caps/tabs (various strengths)Generic DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA, QL (90-180 caps/75 days) ; PA required for age >=19
    Methylphenidate formulations (ER, LA, XR, chewable, solution, tabs) multiple strengthsGeneric DRUG TIER = 1; COVERAGE REQUIREMENTS AND LIMITS = PA, QL (ranges: 90–540 tabs per 75 days or mL limits); PA required for age >=19
    Stimulant and related productsmixedCovered
    methylphenidate hcl chew tab 10 mggeneric product entry with PA, QL (540 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl soln 5 mg/5mlgeneric product, DRUG TIER = 1, PA, QL (5400 mL every 75 days), MO; PA required for age >=19
    methylphenidate hcl soln 10 mg/5mlgeneric product, DRUG TIER = 1, PA, QL (2700 mL every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab 5 mggeneric product, DRUG TIER = 1, PA, QL (540 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab 10 mggeneric product, DRUG TIER = 1, PA, QL (540 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab 20 mggeneric product, DRUG TIER = 1, PA, QL (270 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab er 10 mggeneric product, DRUG TIER = 1, PA, QL (270 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab er 20 mggeneric product, DRUG TIER = 1, PA, QL (270 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab er 24hr 18 mggeneric product, DRUG TIER = 1, PA, QL (180 tabs every 75 days), MO; PA required for age >=19
    methylphenidate hcl tab er 24hr 27 mggeneric product, DRUG TIER = 1, PA, QL (180 tabs every 75 days), MO; PA required for age >=19
    1–10 of 23
    1/3
    Allergenic extracts/biologicalsmixedCovered
    GRASTEK SUB 2800BAU (timothy grass pollen allergen extract)DRUG TIER = 2, COVERAGE REQUIREMENTS = PA, MO
    ODACTRA SUB (dust mite mixed allergen extract)DRUG TIER = 2, COVERAGE REQUIREMENTS = PA, MO
    ORALAIR SUB 300 IR (grass mixed pollens allergen extract)DRUG TIER = 2, COVERAGE REQUIREMENTS = PA, MO
    RAGWITEK SUB (short ragweed pollen allergen extract)DRUG TIER = 2, COVERAGE REQUIREMENTS = PA, MO
    Aminoglycoside nebulizer solutionsmixedCovered
    tobramycin nebu soln 300 mg/4mlDRUG TIER = 1, COVERAGE REQUIREMENTS = SP, PA, QL (8 mL every 1 day)
    tobramycin nebu soln 300 mg/5mlDRUG TIER = 1, COVERAGE REQUIREMENTS = SP, PA, QL (10 mL every 1 day)
    JAK inhibitors / oral and solution formulationsmixedCovered
    RINVOQ LQ SOL 1MG/ML (upadacitinib)DRUG TIER = 2, COVERAGE REQUIREMENTS = SP, PA, QL (12 mL every 1 day); Preferred for Psoriatic Arthritis
    RINVOQ TAB 15MG ER (upadacitinib)DRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (1 tab every 1 day); Preferred for multiple indications
    RINVOQ TAB 30MG ERDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (1 tab every 1 day); Preferred for Crohn's Disease, Ulcerative Colitis
    RINVOQ TAB 45MG ERDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (56 tabs every 56 days); Preferred for Crohn's Disease, Ulcerative Colitis
    XELJANZ SOL 1MG/ML (tofacitinib citrate)DRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (10 mL every 1 day); Preferred for Rheumatoid Arthritis
    XELJANZ TAB 5MGDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (2 tabs every 1 day); Preferred for Rheumatoid Arthritis
    XELJANZ TAB 10MGDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (2 tabs every 1 day); Preferred for Rheumatoid Arthritis
    XELJANZ XR TAB 11MGDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (1 tab every 1 day); Preferred for Rheumatoid Arthritis
    XELJANZ XR TAB 22MGDRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (1 tab every 1 day); Preferred for Rheumatoid Arthritis
    NSAIDs and analgesicsmixedCovered
    celecoxib cap 50 mg / 100 mg / 200 mg / 400 mggeneric entries, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO
    diclofenac potassium tab 50 mggeneric, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO
    diclofenac sodium tab delayed release 25/50/75 mggeneric entries, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO
    diclofenac sodium tab er 24hr 100 mggeneric, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO
    ibuprofen tab 400/600/800 mggeneric entries, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO or blank per row
    ibuprofen susp 100 mg/5mlgeneric, COVERAGE_REQUIREMENTS not specified in this segment
    ibuprofen-famotidine tab 800-26.6 mggeneric, COVERAGE_REQUIREMENTS = PA, MO
    indomethacin cap 25/50 mg, ER 75 mg, suppos 50 mg, susp 25 mg/5mlgeneric entries, COVERAGE_REQUIREMENTS = MO
    ketorolac tromethamine tab 10 mggeneric, COVERAGE_REQUIREMENTS not specified in this segment
    PDE4 inhibitors, pyrimidine synthesis inhibitors, nonnarcotic analgesicsmixedCovered
    OT EZLA / apremilast (various strengths/formulations)Brand OTEZLA and generics, DRUG TIER = 2, COVERAGE_REQUIREMENTS = SP, PA, QL (examples: 55 tabs every 28 days; 2 tabs every day; 41 tabs every 28 days)
    leflunomide tab 10 mg / 20 mggeneric, DRUG TIER = 1, COVERAGE_REQUIREMENTS = MO
    butalbital-acetaminophen 50-325 mggeneric, QL (48 tabs every 25 days)
    butalbital-acetaminophen-caffeine 50-325-40 mggeneric, QL entries follow
    Formulary drug entries and utilization controlsmixed
    apremilast (Otezla) tabs 10/20/30/75 XRPreferred for Psoriasis, Psoriatic Arthritis; Coverage: SP, PA, QL (various QLs shown: e.g., 55 tabs/28 days, 41 tabs/28 days, 2 tabs/day, 1 tab/day)
    leflunomide tab 10 mg, 20 mgDRUG TIER = 1; COVERAGE_REQUIREMENTS = MO
    butalbital-acetaminophen (50-325 mg) and combosDRUG TIER = 1; QL (48 tabs every 25 days)
    aspirin 81 mgDRUG TIER = PV; QL (100 tabs every 30 days); $0 copay for members capable of pregnancy at risk for preeclampsia
    codeine sulfate tab 30 mgDRUG TIER = 1; COVERAGE_REQUIREMENTS = PA, QL (42 tabs every 25 days); Subject to initial 7-day limit; If age 19 or younger, initial 3-day limit
    fentanyl TD patch 72hr (12-100 mcg/hr)DRUG TIER = 1; COVERAGE_REQUIREMENTS = ST (some strengths), QL (10 patches every 25 days); PA or High Strength Requires PA
    hydrocodone bitartrate ER caps/tabs (10-120+ mg)DRUG TIER = 1; COVERAGE = ST or PA depending on strength; QL examples: 60 caps every 25 days; High Strength Requires PA
    hydromorphone (liquid and tabs, ER)DRUG TIER = 1; COVERAGE = PA, QL (varying e.g., 600 mL every 25 days, 180 tabs etc.); initial 7-day limit (3-day if age ≤19)
    meperidine (tabs/solution)DRUG TIER = 1; COVERAGE = PA, QL; initial 7-day limit (3-day if age ≤19)
    methadone formulations (conc, soln, tabs, tabs for oral suspension 40 mg)DRUG TIER = 1; COVERAGE = QL (various), some PA; indicated entries note methadone indicated for opioid addiction for certain formulations
    1–10 of 14
    1/2
    Codes (none provided)mixed
    NDC/HCPCS not specifiedNo explicit procedure, diagnosis, or billing codes provided in this segment; only drug product names, strengths, coverage designations, and QLs are listed.
    Quantity limit codesmixedCovered
    QL (150 tabs every 25 days)Quantity limit applied to alprazolam ODT and multiple alprazolam tablet strengths
    QL (90 tabs every 25 days)Quantity limit applied to alprazolam ER 3 mg
    QL (360 caps every 25 days)Quantity limit applied to chlordiazepoxide 5/10/25 mg
    Coverage requirement codesmixed
    PAPrior authorization required
    MOMedical only
    SPSpecialty
    Anti-inflammatory inhalers (examples)mixedCovered
    fluticasone-salmeterol aer powder ba 250-50 mcg/actGeneric fluticasone-salmeterol dry aerosol powder 250/50 mcg per actuation (QL: 180 inhalations every 75 days), Tier 1
    WIXELA INHUBBrand fluticasone-salmeterol (same strengths), Tier 1, QL 180 inhalations every 75 days
    fluticasone-salmeterol aer powder ba 500-50 mcg/actGeneric fluticasone-salmeterol dry aerosol powder 500/50 mcg per actuation, Tier 1, QL 180 inhalations every 75 days
    Nebulizer solutions and inhalation aerosolsmixedCovered
    formoterol fumarate soln nebu 20 mcg/2mlGeneric formoterol nebulizer solution 20 mcg/2 ml, QL 360 mL every 75 days, Tier 1
    ipratropium-albuterol nebu soln 0.5-2.5(3) mg/3mlGeneric ipratropium-albuterol nebulizer solution, QL 1620 mL every 75 days, Tier 1
    levalbuterol hcl soln nebu 0.31 mg/3mlGeneric levalbuterol nebulizer solution 0.31 mg/3 ml, QL 900 mL every 75 days, Tier 1
    levalbuterol tartrate inhal aerosol 45 mcg/actGeneric levalbuterol inhalation aerosol 45 mcg/act, QL 6 inhalers every 75 days, Tier 1
    SEREVENT DIS AER 50MCG (salmeterol xinafoate)Brand salmeterol aerosol 50 mcg, QL 180 inhalations every 75 days, Tier 2
    Coumarin anticoagulantsmixedCovered
    warfarin sodium tab 1 mg - 10 mgWarfarin sodium tablets various strengths, Tier 1, Coverage: MO
    Direct oral anticoagulants and thrombin inhibitorsmixedCovered
    apixaban (ELIQUIS) various strengthsApixaban tablets/capsules listed with Tier 2 (multiple strengths), Coverage: MO
    rivaroxaban (XARELTO) various strengthsRivaroxaban tablets/suspension, Tier 1-2 depending on presentation, Coverage: MO
    dabigatran etexilate (PRADAXA) cap 75/110/150 mgDabigatran capsules listed, Tier 1, Coverage: MO
    Anticonvulsants (selected)mixedCovered
    perampanel susp/tab (0.5 mg/ml, 2-12 mg)Perampanel oral suspension and tablets, Tier 1, Coverage: MO
    clobazam (suspension and tabs)Clobazam suspension 2.5 mg/ml and tablets 10/20 mg, Tier 1, Coverage: MO
    clonazepam (various ODT/tablet strengths)Clonazepam orally disintegrating tabs and tablets, QL 300 tabs every 25 days for multiple strengths, Tier 1
    diazepam rectal gel (2.5-20 mg)Diazepam rectal gel delivery system various strengths, Tier 1
    NAYZILAM (midazolam) SPR 5MGMidazolam nasal spray, Tier 2
    VALTOCO (diazepam) SPR 5/10/15MGDiazepam nasal spray presentations, Tier 2
    BRIVIACT (brivaracetam) SOL/TAB 10-100 mgBrivaracetam oral solution and tablets, Tier 2, Coverage: MO
    carbamazepine, eslicarbazepine, gabapentin, lacosamide, lamotrigine (multiple strengths/forms)Multiple generic anticonvulsant products listed, Tier 1, Coverage: MO
    Listed formulary drugs in this sectionmixed
    gabapentin 800 mg tabgabapentin tab 800 mg (listed)
    lacosamide 10 mg/ml solnlacosamide oral solution 10 mg/ml
    lacosamide 50 mg tablacosamide tab 50 mg
    lamotrigine ODT 25 mglamotrigine orally disintegrating tab 25 mg
    lamotrigine ODT 50 mglamotrigine orally disintegrating tab 50 mg
    lamotrigine ODT 100 mglamotrigine orally disintegrating tab 100 mg
    lamotrigine tab 25 mglamotrigine tab 25 mg (and starter kits)
    lamotrigine tab 100 mglamotrigine tab 100 mg
    lamotrigine tab 150 mglamotrigine tab 150 mg
    lamotrigine tab 200 mglamotrigine tab 200 mg
    1–10 of 36
    1/4
    Antidepressants (selected entries)NDC|proprietary names
    bupropion hcl tab 100 mglisted product and strength
    bupropion hcl tab er 12hr 150 mglisted product and strength
    bupropion hcl tab er 12hr 200 mglisted product and strength
    bupropion hcl tab er 24hr 150 mglisted product and strength
    bupropion hcl tab er 24hr 300 mglisted product and strength
    ZURZUVAE CAP 20MG (zuranolone)listed product and strength
    ZURZUVAE CAP 25MG (zuranolone)listed product and strength
    ZURZUVAE CAP 30MG (zuranolone)listed product and strength
    SSRIs and MAOIsmixed
    phenelzine sulfate tab 15 mgMAOI product
    tranylcypromine sulfate tab 10 mgMAOI product
    citalopram hydrobromide oral soln 10 mg/5mlSSRI product
    citalopram hydrobromide tab 10 mgSSRI product
    citalopram hydrobromide tab 20 mgSSRI product
    citalopram hydrobromide tab 40 mgSSRI product
    escitalopram oxalate soln 5 mg/5mlSSRI product
    escitalopram oxalate tab 5 mgSSRI product
    escitalopram oxalate tab 10 mgSSRI product
    escitalopram oxalate tab 20 mgSSRI product
    Fluoxetine and related SSRIsmixed
    fluoxetine hcl cap 10 mgSSRI products
    fluoxetine hcl cap 20 mgSSRI products
    fluoxetine hcl cap 40 mgSSRI products
    fluoxetine hcl cap delayed release 90 mgSSRI product
    fluoxetine hcl solution 20 mg/5mlSSRI product
    fluoxetine hcl tab 10 mgSSRI product
    fluoxetine hcl tab 20 mgSSRI product
    Tricyclic agentsmixed
    amitriptyline hcl tab 10 mgTricyclic agent
    amitriptyline hcl tab 25 mgTricyclic agent
    amitriptyline hcl tab 50 mgTricyclic agent
    amitriptyline hcl tab 75 mgTricyclic agent
    amitriptyline hcl tab 100 mgTricyclic agent
    amoxapine tab 25 mgTricyclic agent
    clomipramine hcl cap 25 mgTricyclic agent
    Antidiabetic agents and combinationsmixed
    acarbose tab 25 mgAlpha-glucosidase inhibitor (antidiabetic)
    acarbose tab 50 mgAlpha-glucosidase inhibitor (antidiabetic)
    acarbose tab 100 mgAlpha-glucosidase inhibitor (antidiabetic)
    miglitol tab 25 mgAlpha-glucosidase inhibitor (antidiabetic)
    miglitol tab 50 mgAlpha-glucosidase inhibitor (antidiabetic)
    miglitol tab 100 mgAlpha-glucosidase inhibitor (antidiabetic)
    GLYXAMBI TAB 10-5 MG (empagliflozin-linagliptin)Antidiabetic combination (brand)
    GLYXAMBI TAB 25-5 MG (empagliflozin-linagliptin)Antidiabetic combination (brand)
    SOLIQUA INJ 100/33 (insulin glargine-lixisenatide)Antidiabetic combination (brand)
    SYNJARDY TAB (empagliflozin-metformin)Antidiabetic combination (brand)
    Combination oral agents (partial)mixed
    glyburide-metformin 2.5-500 mgglyburide-metformin tab 2.5-500 mg (generic)
    glyburide-metformin 5-500 mgglyburide-metformin tab 5-500 mg (generic)
    GLYXAMBI 10-5 mgGLYXAMBI TAB 10-5 MG (empagliflozin-linagliptin) (brand)
    GLYXAMBI 25-5 mgGLYXAMBI TAB 25-5 MG (empagliflozin-linagliptin) (brand)
    SGLT2 + metformin combinationsmixed
    SOLIQUA INJ 100/33insulin glargine-lixisenatide (brand)
    SYNJARDYempagliflozin-metformin (brand)
    TRIJARDY XRempagliflozin-linagliptin-metformin (brand)
    XIGDUO XRdapagliflozin-propanediol-metformin (brand)
    BiguanidesNDC|mixedCovered
    metformin 500 mgmetformin hcl tab 500 mg (generic)
    metformin 850 mgmetformin hcl tab 850 mg (generic)
    metformin 1000 mgmetformin hcl tab 1000 mg (generic)
    metformin soln 500 mg/5mlmetformin hcl oral solution 500 mg/5 ml
    Incretin mimetic agents / GLP-1 and dual agonistsmixedCovered
    MOUNJARO (tirzepatide)MOUNJARO INJ (various strengths)
    OZEMPIC (semaglutide)OZEMPIC INJ (various strengths)
    RYBELSUS (semaglutide tabs)RYBELSUS TAB (3,7,14 mg)
    TRULICITY (dulaglutide)TRULICITY INJ (various strengths)
    Insulin productsmixedCovered
    AFREZZAAFREZZA inhaled insulin (various unit sizes)
    FIASP (insulin aspart)FIASP injectable formulations
    LANTUS (insulin glargine)LANTUS INJ 100/ML
    HUMULIN R U-500HUMULIN R INJ U-500
    SGLT2 inhibitors and sulfonylureasmixedCovered
    FARXIGA (dapagliflozin)FARXIGA TAB 5 & 10 MG
    JARDIANCE (empagliflozin)JARDIANCE TAB 10 & 25 MG
    glimepiride 1 mgglimepiride tab 1 mg (sulfonylurea)
    Formulary notice period — member notification
    Formulary notice period60 days
    Opioid prior use thresholds
    Opioid prior use thresholds (ER/IR step therapy)Immediate‑release (IR): cumulative ≥7 days within past 90 days; Extended‑release (ER): cumulative ≥30 days within past 90 days
    Age threshold — stimulants and related products
    Age threshold for amphetamines and many stimulantsPrior authorization required for many amphetamine and methylphenidate products for members age ≥19 years
    Methylphenidate ER/OSM/TD examplesSpecific methylphenidate products listed with PA for age ≥19 (includes ER osmotic release 18, 27, 36, 54, 72 mg; transdermal patches 10/9hr, 15/9hr, 20/9hr, 30/9hr)
    ModafinilModafinil tablets (including 200 mg) listed with PA and MO
    Common quantity limits — examples
    Common quantity limits (representative examples)Examples include 360 tabs every 75 days; 180 tabs every 75 days; 90 caps every 75 days; 540 tabs every 75 days; symptomatic inhaler/neb limits shown separately
    Methylphenidate QLs (selected)Chew/tab/IR: 540 tabs/75 days; ER 10/20 mg: 270 tabs/75 days; ER 18/27/36 mg: 180 tabs/75 days; ER 54/72 mg: 90 tabs/75 days; patches: 90 patches/75 days
    Opioid QL examplesFentanyl patches: 10 patches/25 days (some strengths ST/PA**); morphine solution examples: 900 mL/25 days; oxycodone tabs: 90–180 tabs/25 days depending on product
    Examples of quantity limits — stimulants and related agents
    Examples of quantity limits across stimulant productsAtomoxetine: 360 caps/75 days down to 90 caps/75 days depending on strength; AZSTARYS: 90 caps/75 days; dexmethylphenidate ER: 180–270 caps/75 days; multiple methylphenidate presentations with QL ranges (90–540 tabs/75 days)
    Liquid formulation QLsMethylphenidate solution examples: 5400 mL and 2700 mL per 75 days (depending on concentration)
    WAKIX QLWAKIX (pitolisant) QL = 2 tabs per day
    Quantity limits (examples) — methylphenidate and inhalation products
    Quantity limits (representative listing)Methylphenidate chew tabs: 540 tabs/75 days; ER tabs: 270 or 180 or 90 tabs/75 days by strength; TD patches: 90 patches/75 days; Nebulizer/inhaler examples shown elsewhere (mL or inhalers per 75 days)
    Methylphenidate solution limits5 mg/5 mL: 5400 mL/75 days; 10 mg/5 mL: 2700 mL/75 days
    Levalbuterol and formoterol nebulizer limitsLevalbuterol nebu: 900 mL/75 days (or 6 inhalers); formoterol nebu: 360 mL/75 days
    Initial supply limits — opioids and pediatric constraints
    Initial supply limits for opioidsInitial 7‑day limit for many immediate‑release opioid prescriptions for adults; if member age ≤19, initial supply limit generally 3 days
    Initial supply enforcement examplesMany immediate‑release oral opioids and solutions subject to the 7‑day (adult) / 3‑day (≤19) rule; claims beyond initial limits may require PA
    Pediatric availability noteSome products (e.g., tramadol formulations) are not available for patients under age 12
    Quantity limits (examples) — opioid patches and inhalers
    Additional quantity limit examples (opioid/patch/inhaler)Fentanyl patch examples: 10 patches every 25 days (selected strengths), morphine solution: up to 900 mL/25 days; inhaler examples: 3–9 inhalers per 75 days depending on product
    Buprenorphine patch QLBuprenorphine patches: 4 patches per month (example)
    Fluticasone‑salmeterol inhaler limitFluticasone‑salmeterol dry powder: 180 inhalations every 75 days

    What Providers Must Do

    Prior Authorization

    Prior Authorization, Quantity Limits, Step Therapy — follow PA/ST/QL process

    Sharp Health Plan uses common formulary controls: Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST). Prescribers must request PA or Step Therapy Exceptions when a drug row is marked with PA, PA**, or ST. PA requests will be approved or denied within 72 hours for non‑urgent requests (24 hours for urgent/exigent).

    • Request PA by phone, fax, or electronic PA form and include supporting clinical information.
    • If PA/Step Therapy Exception is incomplete, the plan will request missing information within 72 hours (24 hours exigent).
    • If Sharp fails to respond within the timelines for a completed request, the request is deemed granted.
    Prior Authorization

    PA required for drugs marked 'PA' or 'PA**'

    Prior Authorization is required before Sharp Health Plan will cover drugs labeled 'PA' on the formulary; PA** denotes PA if Step Therapy is not met (providers may still request PA when medically necessary).

    • Providers must submit PA when a product row shows 'PA' or 'PA**'.
    • PA decisions: 72 hours non‑urgent, 24 hours urgent/exigent.
    Prior Authorization

    Obtain PA for Brand‑Name or reference biologic when generic/interchangeable available

    When a generic equivalent exists, the dispensing pharmacy must dispense the generic unless the prescriber obtains prior authorization for the Brand‑Name; similarly, pharmacies may be required to dispense an interchangeable biologic unless PA for the reference biologic is obtained.

    • If requesting the Brand or reference biologic instead of the generic/interchangeable product, submit PA demonstrating medical necessity.
    • Failure to obtain PA may result in the pharmacy dispensing the generic/interchangeable product.
    Prior Authorization

    PA required to dispense Brand‑Name or reference biologic

    Prior authorization is required to dispense Brand‑Name drugs in lieu of an available generic or to receive a reference biologic instead of an interchangeable biological product; pharmacies are required to substitute unless PA is obtained.

    • Prescribers seeking Brand or reference biologic must submit PA supporting medical necessity.
    • Pharmacy will fill generic/interchangeable if PA not approved.
    Prior Authorization

    Amphetamine/stimulant prescriptions: PA, QL, and age documentation

    Many amphetamine and stimulant products require prior authorization and are subject to quantity limits; PA is commonly required for members age ≥19 and prescribers must document patient age in PA requests.

    • Examples of QL: 360 tabs every 75 days, 180 caps every 75 days, 540 tabs every 75 days for certain methylphenidate formulations.
    • PA documentation must include the patient's age when age‑based PA applies (age ≥19).
    Step Therapy

    Opioid ER: Step Therapy prior use requirement

    Certain extended‑release opioid (OPIOID ER) products require step therapy: coverage is provided only when the member has prior opioid exposure (cumulative ≥7 days IR within past 90 days OR cumulative ≥30 days ER within past 90 days) or when step criteria are otherwise met.

    • If step criteria are not met, prescribers must submit PA/Step Therapy Exception with documentation of prior opioid use per the specified timeframe.
    • Opioid ER claims may be denied without prior exposure documentation.
    Prior Authorization

    PA required for many listed stimulant and anti‑obesity products

    Prior authorization is required for the majority of listed amphetamine, anti‑obesity, ADHD, and related products; review each formulary row and submit PA when the COVERAGE REQUIREMENTS field shows 'PA'.

    • Providers should confirm QL and age limits on the product row when submitting PA.
    • PA decisions follow standard timelines (72/24 hours).
    Billing Rule

    WAKIX: Specialty pharmacy routing + PA + QL (2 tabs/day)

    WAKIX (pitolisant) is designated SP (specialty), requires prior authorization, and is subject to a quantity limit of 2 tablets per day; dispense only via specialty channel unless authorized otherwise.

    • Submit PA for WAKIX and ensure specialty pharmacy routing.
    • Quantity limit: 2 tabs every 1 day as listed.
    Prior Authorization

    Methylphenidate/stimulant PA and QL for adults (age ≥19)

    Many methylphenidate formulations require prior authorization for members age ≥19 and are subject to quantity limits; prescribers must include age and supporting information in PA requests.

    • QL examples for methylphenidate: 540 tabs/75 days, 270 tabs/75 days, 90 tabs/75 days, and liquid mL limits (e.g., 5400 mL/75 days).
    • PA required for members age greater than or equal to 19.
    Billing Rule

    Specialty drugs: SP designation requires specialty routing + PA (+ QL)

    Specialty products (SP) require specialty pharmacy routing and prior authorization; many SP products also carry quantity limits and must be dispensed through the plan’s specialty channel (e.g., tobramycin nebulizer solutions, upadacitinib, apremilast).

    • Submit PA and follow specialty pharmacy site‑of‑care requirements (30‑day supply limits per specialty policy).
    • Include documentation to satisfy QL and SP routing in the PA request.
    Prior Authorization

    PA required for many opioid ER/patch/high‑strength formulations

    Prior authorization is required for many extended‑release, patch, and high‑strength opioid formulations; high‑strength products are specifically labeled 'High Strength Requires PA' on product rows.

    • Prescribers must document prior opioid therapy and clinical justification when requesting PA for high‑strength products.
    • Some ER/patch strengths are also subject to step therapy (ST) or PA**.
    Prior Authorization

    PA required for buprenorphine/belbuca and other opioid products

    Prior authorization (PA or PA**) is required for many opioid and related products including specific strengths of buprenorphine/belbuca patches and films; high‑strength buprenorphine products also require PA.

    • BUprenorphine patches/films: check product row for ST/PA/PA** and QL before dispensing.
    • Provide documentation of medical necessity for high‑strength buprenorphine products when submitting PA.
    Prior Authorization

    Submit PA where the formulary row indicates 'PA'

    Medications labeled with 'PA' in the Coverage Requirements and Limits column require prior authorization before coverage; review product rows (examples include testosterone products and others) and submit PA when indicated.

    • Examples: methyltestosterone 10 mg and several testosterone gels list PA and MO.
    • Follow the PA submission process and include requested supporting documentation.
    Prior Authorization

    PA required for select antiarrhythmics (e.g., dofetilide)

    Select antiarrhythmic agents (e.g., dofetilide) carry specialty (SP) and prior authorization flags; submit PA and anticipate specialty routing for these agents.

    • Dofetilide capsule strengths (125, 250, 500 mcg) require SP and PA.
    • Include clinical justification and any site‑of‑care instructions in the PA.
    Billing Rule

    PA required when requests exceed quantity limits or MO notes

    Several products include explicit quantity limits (QL) or 'MO' notes; requests that exceed QL or initial supply limits require prior authorization and may be denied if limits are not met.

    • Examples: inhalers QL (e.g., 180 inhalations/75 days), methylphenidate QLs, and OTEZLA QL (55 tabs/28 days).
    • If requesting quantities beyond QL, submit PA documenting medical necessity.
    Prior Authorization

    PA/SP/QL required for vigabatrin (VIGADRONE)

    Vigabatrin (powder pack/tab 500 mg; VIGADRONE) is designated SP, requires prior authorization, and is subject to a quantity limit (6 packets/tabs every 1 day); submit PA with specialty routing and documentation.

    • VIGADRONE and generic vigabatrin rows: SP, PA, QL (6 packets or tabs every day).
    • Specialty PA submission required for coverage.
    Prior Authorization

    PA/SP/QL required for zuranolone (ZURZUVAE) caps

    Zuranolone (ZURZUVAE) products are designated SP, require prior authorization, and are subject to quantity limits (1–2 caps per day depending on listing); submit PA including specialty routing and requested QL.

    • ZURZUVAE 20 mg: SP, PA, QL = 2 caps every 1 day; other ZURZUVAE listing: SP, PA, QL = 1 cap every 1 day.
    • Include clinical justification in the PA for zuranolone.
    Prior Authorization

    PA and QL requirements for select neuroactive and injectable specialty drugs

    Certain neuroactive agents and select specialty products require PA plus QL and specialty routing (e.g., zuranolone, vigabatrin, selected incretin mimetics); submit PA with documentation of indication and requested quantity limits.

    • GLP‑1/dual agonists (tirzepatide, semaglutide, dulaglutide) list PA (and often MO); submit PA for these injectable agents.
    • Provide required clinical documentation and route to specialty pharmacy when SP is indicated.
    Prior Authorization

    PA required for many GLP‑1 receptor agonists and tirzepatide

    Many GLP‑1 receptor agonists and tirzepatide products (e.g., MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) require prior authorization per the formulary listings; submit PA for these incretin mimetic agents.

    • Injectable GLP‑1s are often also labeled MO; include documentation if medical override applies.
    • Prescribers should follow PA process for all listed GLP‑1/dual agonist strengths.
    Step Therapy

    Step Therapy: follow ST rules and submit exceptions when justified

    Formulary contains step therapy rules and class‑specific tables; drugs marked 'ST' require trial of preferred alternatives first and providers may request Step Therapy Exceptions with clinical justification.

    • Step Therapy Exception requests follow the PA process and are reviewed within 72 hours (24 hours exigent).
    • Continuity of care from a prior insurer may exempt a member from Step Therapy.
    Step Therapy

    Weight‑loss drugs: enrollment in weight‑loss program may be required

    Enrollment in a comprehensive weight‑loss program may be required as a Step Therapy requirement prior to or concurrent with coverage of certain weight‑loss drugs when medically necessary for Class III obesity.

    • When coverage is provided for Class III obesity, include evidence of enrollment in the weight‑loss program in the PA or Step Therapy Exception request.
    • Examples: WEGOVY and phentermine/topiramate products list PA and may require program participation per formulary notes.
    Note

    Formulary is subject to change — confirm current coverage and PA/ST/QL flags

    Document is subject to change and previous versions are no longer in effect; providers should verify current formulary status online (sharphealthplan.com/search-drug-list) to confirm PA/QL/ST requirements before prescribing.

    • Sharp will provide 60 days’ notice to members for negative formulary changes.
    • Providers should reference the electronic formulary for the most current coverage flags and limits.
    Denial Risk

    Denial risk if PA is not obtained

    Failure to obtain required prior authorization when the formulary indicates 'PA' may result in denial of coverage.

    • Denials may be appealed; appeal and grievance processes are described in the formulary.
    • If PA is denied, the member or provider may file an appeal.
    Denial Risk

    Exclusion categories that can trigger denial — confirm indication

    Prescriptions for drugs used for excluded purposes (e.g., cosmetic uses, hair loss, sexual dysfunction, athletic performance, anti‑aging for cosmetic purposes, or non‑covered weight loss) may be denied under the outpatient prescription benefit.

    • Exceptions apply when use is medically necessary for diagnosed conditions or required by law.
    • Confirm indication in PA submission when coverage for such uses is requested.
    Denial Risk

    Opioid ER step therapy denial risk without documented prior exposure

    Opioid ER/ST denials: extended‑release opioid coverage may be denied unless prior opioid exposure criteria are documented (cumulative ≥7 days IR within 90 days OR cumulative ≥30 days ER within 90 days).

    • If member lacks prior exposure, consider short‑supply allowance for IR combos (up to a 7‑day supply) where applicable and documented.
    • Include dispensing history and dates/quantities in PA to meet step criteria.
    Denial Risk

    Amphetamine PA denial risk for patients age ≥19 — include age in PA

    Claims for amphetamine products dispensed to members age ≥19 without prior authorization may be denied; prescribers must document patient age in PA requests.

    • Many amphetamine entries explicitly state 'PA Required for age greater than or equal to age 19.'
    • Include age and clinical rationale when submitting PA for adult stimulant therapy.
    Note

    Quantity limits and initial supply limits — PA required if exceeding limits

    Requests that exceed listed quantity limits (QL) or initial supply limits (initial 7‑day for adults; 3‑day for age ≤19) may be denied or require PA; prescribers should request PA if larger quantities or longer supplies are clinically necessary.

    • Initial supply limits: many immediate‑release opioids subject to 7‑day initial limit; age ≤19 subject to 3‑day initial limit.
    • Provide justification for continued supplies beyond initial limits in the PA documentation.
    Prior Authorization

    PA/SP requirement for select antiarrhythmics (dofetilide)

    Dofetilide and other antiarrhythmics flagged SP/PA require prior authorization and specialty routing; coverage may be denied if PA/SP routing is not followed.

    • Dofetilide capsule strengths list SP and PA—submit specialty PA with required clinical information.
    • Anticipate specialty site‑of‑care instructions when SP is indicated.
    Documentation Required

    Prescription and PA submission content requirements

    Prescriptions must include necessary prescription content (prescriber identity and contact, patient name, drug name, quantity, date, and signature if written); include clinical indication when requested by the enrollee or plan.

    • Ensure PA submissions include prescriber contact and relevant clinical documentation to avoid incomplete request processing.
    • Incomplete PA/Step Therapy Exception requests will trigger a request for additional information within plan timelines.
    Documentation Required

    How to submit PA and handling of incomplete requests

    Prescribers must submit Prior Authorization requests by phone, fax, or electronic form and include supporting clinical documentation; if a request is incomplete, the plan will notify the provider what additional information is needed within 72 hours (24 hours exigent).

    • Include clinical history, prior therapies, dates/quantities dispensed, and patient age where relevant (e.g., stimulants, opioids).
    • Follow up to ensure PA is completed within the stated decision timeframe.
    Billing Rule

    Pharmacy dispensing rules: generic/interchangeable substitution unless PA obtained

    Pharmacy must dispense the generic when a generic equivalent exists unless prior authorization for the Brand‑Name drug is obtained; similarly, pharmacy may be required to dispense an interchangeable biological product unless PA for the reference biologic is obtained.

    • If prescriber requires Brand or reference biologic, submit PA showing medical necessity for the non‑preferred product.
    • Pharmacies follow substitution rules per formulary unless PA authorizes otherwise.
    Documentation Required

    Documentation expectations for high‑strength opioids and continued supplies

    Prescribers should expect to provide specific documentation when requesting PA for high‑strength opioids or continued supplies beyond initial limits, including prior opioid exposure history and clinical justification.

    • Document prior opioid fills (dates and days supplied) to satisfy opioid ER step therapy criteria.
    • Provide rationale for high‑strength dosing and need for quantities beyond QL in the PA.
    Prior Authorization

    PA/SP/QL for vigabatrin and zuranolone — include specialty documentation

    PA is required for vigabatrin (powder pack/tab 500 mg, VIGADRONE) and zuranolone (ZURZUVAE) as listed, and these products are designated SP with strict QL; submit specialty PA and include required monitoring/justification.

    • Vigabatrin: SP, PA, QL = 6 packets/tabs every day.
    • Zuranolone: SP, PA, QL = 1–2 caps per day depending on listing.
    Documentation Required

    Respond to coverage flags (PA, PA**, ST, QL, SP, MO) on product rows

    Formulary coverage flags (MO, PA, SP, QL) appear next to product listings; when a product is flagged, providers must supply the documentation appropriate to that flag when requesting coverage.

    • MO indicates medical/monitoring/medical‑only conditions — include justification in PA when requested.
    • SP requires specialty routing; QL indicates the maximum quantity covered per period.
    Documentation Required

    Ensure prescriptions conform to coverage requirements and QL or submit PA

    Prescriptions and PA requests should conform to the listed coverage requirements and quantity limits; nonconforming requests (e.g., quantities above QL, missing PA) can be denied or require PA to override.

    • If a request exceeds QL, submit PA with medical necessity for the excess quantity.
    • If PA is required per the formulary row, obtain authorization prior to dispensing to avoid denial.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy Requirements

    Initial therapy for stimulants

    Initial therapy criteria for stimulant products (stimulants are covered when conditions below are met):

    Initial stimulant coverage: Coverage is permitted when Prior Authorization is obtained for members age ≥19 and the dispensed quantity does not exceed the product‑specific Quantity Limit shown on the Formulary row.age >=19; QL as listed

    Examples: methylphenidate entries show PA and QL values

    Initial therapy limits

    Initial therapy limits for oral opioids and solutions:

    Initial therapy restrictions for opioids: Many immediate‑release opioid liquid and tablet products are subject to an initial 7‑day supply limit for adults; members age 19 or younger are subject to an initial 3‑day limit. Prescribers should request Prior Authorization for supplies beyond the initial limit.Initial 7‑day adult / 3‑day <=19

    Applies to multiple oral opioid solutions and tablets (see product rows)

    Initial supply limits

    Initial supply limits applied to many opioid products (operational guidance):

    Initial supply rules: Most immediate‑release opioid prescriptions are processed with an initial 7‑day supply limit for adults; where specified, members age 19 or younger are subject to a 3‑day initial limit. Requests exceeding initial limits will require Prior Authorization with clinical justification.7 days (adult) / 3 days (<=19 years)

    Enforced across multiple product rows; see product QL and PA flags

    Step Therapy Rules & Tables

    Step Therapy overview
    Sharp Health Plan may require an enrollee to try one or more drugs (a 'step' approach) before the Plan will cover a requested drug; providers may submit a Step Therapy Exception with supporting clinical documentation and the Plan will grant exceptions when criteria are met.
    Step approach requirement
    Drugs marked 'ST' on the Formulary require Step Therapy (trial of a preferred alternative first). Providers may request a Step Therapy Exception via the Prior Authorization process; continuity of therapy from a prior insurer may be honored without requiring step therapy.
    Weight-loss program requirement
    When weight‑loss drugs are covered for Class III obesity, enrollment in a comprehensive weight‑loss program (if covered by the Plan) may be required prior to or concurrent with receiving the prescription drug.
    Opioid prior exposure requirement
    Coverage for extended‑release (ER) opioid agents is provided only if the member has either: (a) filled a cumulative ≥7‑day supply of an immediate‑release opioid within the past 90 days, OR (b) been receiving an extended‑release opioid for a cumulative ≥30 days within the past 90 days. Immediate‑release opioid combination products may be covered for up to a 7‑day supply if no recent cumulative 7‑day opioid supply exists.
    No explicit step sequences
    The Formulary uses ST flags to indicate Step Therapy requirements, but detailed sequential step‑by‑step treatment pathways are not provided in these excerpts; only the presence of ST and instructions for requesting exceptions are shown.
    Specialty preferred indications noted
    Some specialty agents are annotated as 'Preferred for' specific diagnoses (example: RINVOQ and OTEZLA preferred for psoriatic disease or related indications), but the listing does not present an explicit step hierarchy linking these preferred agents to other formulary drugs in this excerpt.
    ER/transdermal opioid ST
    Selected extended‑release and transdermal opioid products are designated ST (step therapy) in the formulary (examples: multiple fentanyl patch strengths and certain morphine ER products); some high‑strength transdermal patches and ER formulations additionally require PA or are identified as high‑strength requiring PA.
    Step therapy designated products
    Multiple products across therapeutic classes are designated ST in the coverage table (examples include certain tramadol ER strengths, acetaminophen/codeine combinations, and buprenorphine patches), indicating that a trial of preferred agents is required before coverage of the listed product.
    Inhaled agents step edits
    Some inhaled agents include QL and MO modifiers (quantity limits and medical/monitoring notes); the formulary instructs to follow configured plan step edits where present (managed edits applied in the pharmacy system).
    No step sequences specified in section
    In portions of the formulary extract only tiering and coverage annotations (PA, SP, QL, MO) are shown; explicit step therapy sequences are not provided in these sections.
    Step therapy not explicitly detailed
    The coverage listings include ST flags and other coverage indicators, but the excerpt does not include detailed step‑therapy sequencing or step order — only coverage flags and per‑product notes are present.
    PA required for many incretin mimetics
    Multiple injectable incretin mimetic agents (GLP‑1 receptor agonists and tirzepatide products such as MOUNJARO, OZEMPIC, and liraglutide) are listed with 'PA' (prior authorization) and in some cases 'MO', indicating that prior authorization is required for coverage of these agents.

    Quantity Limits & Examples

    Formulary notice period60 days written notice to negatively affected members
    Opioid ER prior use thresholdsIR ≥7 days within past 90 days OR ER ≥30 days within past 90 days to qualify for ER coverage
    Initial supply limits summaryInitial 7‑day limit for adults; 3‑day limit for members age ≤19 for many opioids
    Amphetamine (amphetamine/dextroamphetamine) example QL360 tabs every 75 days (selected immediate formulations)
    Age PA notePA required for age ≥19 for many amphetamine entries
    MO/retail noteSome entries include MO (maintenance) allowing 90‑day mail order fills
    Amphetamine‑dextroamphetamine ER caps example180 caps every 75 days (some ER strengths) and 270 caps/75 days for other strengths)
    PA age requirementPA required for age ≥19 for listed ER cap strengths
    MO annotationEntries often include MO indicating maintenance/mail order eligibility
    Dextroamphetamine oral solution example3600 mL every 75 days (5 mg/5 mL solution)
    Brand examplePROCENTRA listed as equivalent solution with same QL
    Age PA notePA required for age ≥19 for liquid presentations
    Lisdexamfetamine examples180 tabs/caps every 75 days for multiple strengths
    PA thresholdPA commonly required for members age ≥19
    QL formatExpressed as quantity per 75 days in formulary rows
    Atomoxetine caps QL example360 caps every 75 days (varies by strength down to 90 caps/75 days)
    PA age requirementPA required for age ≥19 for many atomoxetine entries
    MO noteMany entries include MO alongside QL and PA
    AZSTARYS caps example90 caps every 75 days
    WAKIX contrastWAKIX is SP, PA, QL (2 tabs/day) rather than 75‑day cycle
    Age/PA notePA commonly required for age ≥19 on some ADHD agents
    WAKIX quantity limit2 tabs per day (SP, PA, QL)
    Specialty routingWAKIX designated SP — specialty pharmacy dispensing required
    PA requirementPrior authorization required for WAKIX
    Methylphenidate chew tab QL540 tabs every 75 days
    Applied toChewable and some immediate formulations of methylphenidate
    PA age rulePA required for age ≥19
    Methylphenidate solution 5 mg/5 mL QL5400 mL every 75 days
    Methylphenidate solution 10 mg/5 mL QL2700 mL every 75 days
    Methylphenidate chew/tab 10 mg example540 tabs every 75 days
    Methylphenidate chew tab 10 mg example540 tabs every 75 days
    Methylphenidate ER tab 10 mg example270 tabs every 75 days
    ER 54 mg example90 tabs every 75 days
    Methylphenidate solution 5 mg/5 mL example5400 mL every 75 days
    Methylphenidate solution 10 mg/5 mL example2700 mL every 75 days
    ER and osmotic release examplesER and OSM formulations have QLs of 180–90 tabs per 75 days depending on strength
    Methylphenidate ER tab 10 mg QL270 tabs every 75 days
    Methylphenidate ER 54 mg QL90 tabs every 75 days
    TD patch QL90 patches every 75 days (10/15/20/30 mg/9hr)
    Methylphenidate ER 10 mg tab example (270) and ER 54 mg (90)270 or 90 tabs per 75 days depending on strength
    TD patch example90 patches every 75 days (all listed strengths)
    PA age rule reminderPA required for age ≥19 across methylphenidate product rows
    Tobramycin nebulizer solution 300 mg/4 mL QL8 mL every 1 day (SP, PA)
    Tobramycin nebulizer solution 300 mg/5 mL QL10 mL every 1 day (SP, PA)
    Specialty dispensedDesignated SP — specialty pharmacy routing required
    Tobramycin nebu 300 mg/5 mL QL10 mL every 1 day
    SP/PA designationRequires specialty pharmacy and prior authorization
    Used forAminoglycoside nebulizer therapy — QL set per day
    OTEZLA (apremilast) tablets QL55 tabs every 28 days (SP, PA, QL)
    Alternate OTEZLA listingsSome OTEZLA entries list 2 tabs every 1 day or 41 tabs every 28 days depending on presentation
    Specialty/PAOTEZLA designated SP and PA in rows shown
    RINVOQ TAB 45 mg ER QL56 tabs every 56 days (SP, PA, QL)
    Other RINVOQ formsRINVOQ solutions/tabs have daily QLs (1 tab/day) for some strengths
    Specialty designationRINVOQ products listed SP, PA, QL
    Butalbital‑acetaminophen (50/325) QL48 tabs every 25 days
    Combination productsButalbital combinations have similar 48‑tab/25‑day limits
    TieringTypically Tier 1 with QL applied
    Opioid/patch varied QL examplesFentanyl patches: up to 10 patches/25 days (some strengths); Morphine solution examples 900 mL/25 days; Hydrocodone: 60 caps/25 days; Oxycodone: 180 tabs/25 days
    High strength warningHigh‑strength formulations require PA or are flagged PA**/ST
    Initial supply noteMany entries subject to initial 7‑day limit (3‑day if age ≤19)
    Aspirin 81 mg QL example100 tablets every 30 days (PV tier for select pregnancy prevention use)
    Copay note$0 copay for members capable of pregnancy age 12‑59 at risk for preeclampsia
    OtherwiseAspirin entry may be limited or not covered outside preventive criteria
    Common QL values across listExamples include 60, 90, 150, 180, 240, 360 tabs per 25 days or 75‑day cycles depending on product
    Tab/mL/inhaler unitsQLs specified in tabs, mL, inhalers, or inhalations per period
    EnforcementRequests exceeding QL require PA and may be denied
    Alprazolam QL examples150 tabs every 25 days for many strengths; 90 tabs every 25 days for ER 3 mg
    ODT and ER distinctionsODT and ER forms may have different QLs specified in rows
    Provider notePA not typically required for alprazolam but QL enforced
    Chlordiazepoxide QL360 caps every 25 days
    UsageApplies to 5/10/25 mg capsule strengths listed
    QL periodSpecified per 25‑day cycle
    Alprazolam various QLs150 tabs every 25 days for many strengths; 90 tabs every 25 days for some ER strengths
    ODT forms includedOrally disintegrating tablets have same 150‑tab/25‑day QL in many entries
    Enforcement noteQLs are enforced per formulary row; PA required to exceed
    Diazepam QL examples240 mL every 25 days (5 mg/mL); 1200 mL every 25 days (1 mg/mL); 120 tabs every 25 days
    Solution and tablet distinctionsDifferent concentrations have separate mL QLs
    QL period25‑day cycle for listed benzodiazepine QLs
    Inhaler/nebulizer QL examples3/6/9 inhalers every 75 days; 720 mL/75 days; 1125 mL/75 days; 1620 mL/75 days for some neb solutions
    Fluticasone‑salmeterol inhaler QL180 inhalations every 75 days
    Nebulizer solution examplesFormoterol 360 mL/75 days; Levalbuterol 900 mL/75 days
    Fluticasone‑salmeterol 250‑50 & 500‑50 QL180 inhalations every 75 days
    WIXELA / equivalent entriesListed with same 180 inhalation QL
    QL period75‑day cycle
    Formoterol nebulizer QL360 mL every 75 days
    Ipratropium‑albuterol nebu QL1620 mL every 75 days
    Levalbuterol nebu/inhaler QL900 mL (nebu) or 6 inhalers every 75 days
    Ipratropium‑albuterol nebu soln QL1620 mL every 75 days
    Levalbuterol nebu/inhaler QL900 mL (nebu) or 6 inhalers every 75 days
    TRELEGY QL3 inhalers every 75 days
    Clonazepam ODT QL300 tabs every 25 days
    Applies toOrally disintegrating and standard clonazepam tablets listed
    QL period25‑day cycle
    TRELEGY AER QL3 inhalers every 75 days
    ClassFluticasone‑umeclidinium‑vilanterol combination inhaler
    MO noteOften listed with MO (maintenance) designation
    Vigabatrin QL6 packets or 6 tabs every 1 day (SP, PA, QL)
    Specialty/PAVIGADRONE and generic vigabatrin designated SP and PA
    UnitPer‑day QL (packets/tabs)
    Zuranolone (ZURZUVAE) QL1–2 caps every 1 day; ZURZUVAE 20 mg: 2 caps/day; other listings 1 cap/day
    DesignationSP, PA, QL noted for zuranolone entries
    Daily dosing capQuantity limits expressed per day for this neuroactive steroid class
    ZURZUVAE 20 mg QL2 caps every 1 day (SP, PA, QL)
    Other ZURZUVAE listings1 cap every 1 day for other strengths as listed
    PA/SPPrior authorization and specialty routing required where flagged
    Mifepristone 300 mg QL4 tablets every 1 day (SP, PA, QL)
    DesignationListed with SP and PA in coverage row
    UnitCourse limit expressed as 4 tablets per day

    Specialty, Mail Order & Retail Routing

    Note
    Note
    Note
    Note

    Biologics & Interchangeable Products

    Note
    Note

    Background & Scope

    This document is the Sharp Health Plan Formulary: a prescription drug list organized by therapeutic classes, drug tiers, and coverage controls. The Formulary describes outpatient drugs covered under the pharmacy benefit and explains core processes such as Prior Authorization, Step Therapy, Quantity Limits, specialty routing, and how to request exceptions. Member resources and operational details (for example, where to locate the electronic drug list and how often the formulary changes) are provided on the plan website and in the Member Handbook.

    A Formulary is the plan’s list of covered outpatient prescription drugs, arranged by drug tier and therapeutic category. It indicates which drugs are covered under the pharmacy benefit and the applicable coverage annotations (e.g., PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, SP = Specialty). Definitions of these terms and where to find more information are included in the Formulary and Member Handbook.

    Key Terms & Symbols

    Key formulary terms
    PA (Prior Authorization)Requires Sharp Health Plan authorization before coverage; used where PA symbol appears
    QL (Quantity Limit)Limits drug to specified quantity per prescription/time period not to exceed FDA max; PA required for excess
    ST (Step Therapy)Requires trial of preferred alternative prior to coverage; exceptions may be requested
    Drug Tier
    Drug Tier definitionDrugs are assigned to tiers (PV, 1, 2, 3) which determine member cost‑sharing; consult member benefits for copay/coinsurance details
    PV tier usePV denotes preventive drugs covered with no copayment when indicated (e.g., certain OTC contraceptives)
    Tier accessTier assignment shown next to each product row in formulary
    Formulary symbols
    Formulary symbolsPA = Prior Authorization; PA** = Prior Authorization if Step Therapy not met; QL = Quantity Limit; ST = Step Therapy; MO = Mail Order/90‑day; SP = Specialty
    QL meaningSpecifies maximum quantity per prescription/time period (examples shown per product row)
    SP meaningSpecialty drugs requiring specialty pharmacy dispensing and typically limited to 30‑day fills
    Initial supply limits
    Initial supply limits (definition)Many immediate‑release opioids are subject to an initial 7‑day supply limit for adults; members age ≤19 are subject to an initial 3‑day limit
    Applies toIR opioid liquids, tablets, and many oral formulations as specified per product rows
    EnforcementRequests beyond initial supply require PA and documentation; exceeding limits may be denied